Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BOXX | -9.93% | $5.72B | 0.1949% |
SHYM | -9.20% | $315.75M | 0.35% |
IGV | -9.14% | $9.97B | 0.41% |
BTAL | -7.98% | $404.97M | 1.43% |
SCHO | -7.90% | $10.95B | 0.03% |
VDC | -7.30% | $7.31B | 0.09% |
VIXY | -7.04% | $195.31M | 0.85% |
HYZD | -7.02% | $179.99M | 0.43% |
BAB | -7.00% | $970.93M | 0.28% |
GOVZ | -6.91% | $288.61M | 0.1% |
PHDG | -6.84% | $114.12M | 0.39% |
TAIL | -6.68% | $86.92M | 0.59% |
ULST | -6.57% | $587.03M | 0.2% |
DAPP | -6.49% | $135.15M | 0.51% |
SKYY | -6.47% | $3.13B | 0.6% |
FSTA | -6.36% | $1.26B | 0.084% |
XLP | -6.15% | $16.50B | 0.09% |
ZROZ | -6.11% | $1.57B | 0.15% |
DRSK | -6.05% | $1.14B | 0.78% |
LTPZ | -5.95% | $731.29M | 0.2% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SUNS | 26.90% | $148.58M | -2.04% | 8.44% |
GXO | 25.70% | $4.67B | -25.75% | 0.00% |
BASE | 24.57% | $836.33M | -39.79% | 0.00% |
PGEN | 23.66% | $438.12M | +4.20% | 0.00% |
ALEC | 21.62% | $121.88M | -80.03% | 0.00% |
ARWR | 20.98% | $1.75B | -54.89% | 0.00% |
IRWD | 20.91% | $235.24M | -82.93% | 0.00% |
ACET | 20.81% | $62.43M | -68.54% | 0.00% |
GLPG | 20.56% | $1.66B | -22.66% | 0.00% |
TOST | 19.48% | $19.07B | +36.33% | 0.00% |
PLCE | 19.24% | $111.74M | -19.22% | 0.00% |
AMED | 19.22% | $3.04B | +0.23% | 0.00% |
HAE | 19.19% | $3.19B | -25.05% | 0.00% |
BPT | 19.04% | $11.83M | -77.88% | 0.00% |
MNST | 18.71% | $56.95B | +1.35% | 0.00% |
QTTB | 18.62% | $20.13M | -90.83% | 0.00% |
CDLX | 18.58% | $94.80M | -87.41% | 0.00% |
GALT | 18.24% | $76.02M | -50.00% | 0.00% |
FATE | 18.18% | $90.54M | -88.84% | 0.00% |
TPL | 18.07% | $30.45B | +135.21% | 0.42% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
KCCA | 17.74% | $109.47M | 0.87% |
INFL | 14.05% | $1.13B | 0.85% |
LIT | 13.38% | $937.33M | 0.75% |
GNOM | 13.26% | $53.29M | 0.5% |
KRBN | 13.05% | $173.49M | 0.85% |
ZIG | 12.84% | $36.82M | 0.84% |
CLOI | 12.57% | $1.02B | 0.4% |
ICLO | 12.53% | $354.53M | 0.2% |
ITB | 12.08% | $2.40B | 0.39% |
REMX | 12.02% | $262.64M | 0.56% |
MDIV | 11.71% | $450.20M | 0.68% |
ENZL | 11.19% | $69.77M | 0.5% |
YOLO | 11.12% | $23.28M | 1.03% |
BATT | 11.08% | $57.75M | 0.59% |
TAN | 11.01% | $738.52M | 0.71% |
CLOA | 10.98% | $786.72M | 0.2% |
PXJ | 10.93% | $32.46M | 0.66% |
SLX | 10.86% | $75.82M | 0.56% |
ICLN | 10.82% | $1.32B | 0.41% |
CPSJ | 10.77% | $32.78M | 0.69% |
Current Value
$0.291 Year Return
Current Value
$0.291 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CCRN | -56.83% | $488.58M | -19.25% | 0.00% |
CYCN | -51.01% | $6.78M | -18.57% | 0.00% |
PSTG | -23.89% | $14.44B | -14.96% | 0.00% |
CRM | -19.44% | $257.89B | -11.22% | 0.45% |
MRVL | -18.99% | $53.32B | -15.89% | 0.39% |
SN | -18.95% | $11.71B | +35.25% | 0.00% |
CMG | -18.34% | $68.05B | -12.74% | 0.00% |
PRO | -17.21% | $905.21M | -47.72% | 0.00% |
DPZ | -17.20% | $15.76B | -6.98% | 1.36% |
SWI | -17.16% | $3.19B | +57.39% | 0.00% |
CHEF | -17.05% | $2.23B | +47.75% | 0.00% |
VRNT | -16.59% | $1.11B | -45.03% | 0.00% |
VSTA | -16.20% | $363.18M | +12.97% | 0.00% |
YETI | -15.75% | $2.74B | -13.76% | 0.00% |
TKO | -15.22% | $12.46B | +77.31% | 0.25% |
HELE | -14.56% | $1.22B | -53.40% | 0.00% |
SOUN | -14.30% | $3.24B | +46.04% | 0.00% |
BRFS | -13.86% | $5.58B | +12.26% | 0.00% |
DAKT | -13.63% | $607.70M | +21.56% | 0.00% |
MTN | -13.23% | $5.97B | -27.95% | 5.60% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
NEAR | -<0.01% | $3.23B | 0.25% |
FEMB | 0.01% | $143.56M | 0.85% |
SPLV | 0.01% | $7.69B | 0.25% |
IBD | -0.01% | $381.57M | 0.44% |
ISTB | 0.01% | $4.27B | 0.06% |
SPEU | -0.01% | $1.08B | 0.07% |
USFR | -0.02% | $18.41B | 0.15% |
FLCO | -0.02% | $563.63M | 0.35% |
TESL | -0.04% | $16.08M | 1.2% |
FRDM | -0.04% | $894.01M | 0.49% |
IVW | -0.05% | $51.40B | 0.18% |
IBDY | 0.05% | $718.31M | 0.1% |
AMDY | 0.06% | $144.38M | 1.23% |
ITEQ | 0.07% | $86.43M | 0.75% |
FXG | -0.07% | $287.94M | 0.63% |
IBDX | 0.08% | $1.04B | 0.1% |
MILN | -0.09% | $113.49M | 0.5% |
JEPI | 0.10% | $39.11B | 0.35% |
IYH | 0.10% | $3.18B | 0.39% |
VGT | -0.10% | $75.61B | 0.09% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BIO | -<0.01% | $6.82B | -28.15% | 0.00% |
FDUS | <0.01% | - | - | 8.42% |
RXO | 0.01% | $3.12B | -11.66% | 0.00% |
WLK | 0.01% | $12.83B | -35.15% | 2.09% |
IMNN | 0.02% | $15.35M | -45.60% | 0.00% |
MOFG | 0.02% | $616.35M | +29.81% | 3.31% |
GGAL | -0.02% | $7.22B | +111.25% | 0.52% |
HAIN | 0.02% | $374.52M | -44.59% | 0.00% |
PEN | -0.02% | $10.30B | +23.01% | 0.00% |
DDS | 0.02% | $5.70B | -20.30% | 0.28% |
LNT | 0.02% | $16.52B | +29.53% | 3.03% |
CCL | -0.02% | $25.62B | +20.11% | 0.00% |
AMZN | -0.03% | $2.02T | +5.13% | 0.00% |
CVLG | -0.03% | $537.25M | -3.35% | 1.82% |
KGC | 0.04% | $15.52B | +104.71% | 0.96% |
TR | 0.04% | $2.25B | +2.19% | 1.14% |
BECN | 0.05% | $7.64B | +23.42% | 0.00% |
CTO | 0.05% | $614.88M | +13.59% | 7.77% |
CSTL | -0.05% | $570.85M | -10.02% | 0.00% |
BYRN | 0.06% | $381.37M | +15.34% | 0.00% |
Yahoo
Q4 2024 Relmada Therapeutics Inc Earnings Call
Yahoo
Relmada Therapeutics Inc (RLMD) reports improved cost management and strategic growth initiatives, despite a significant cash burn and ongoing net losses.
SeekingAlpha
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBrian Ritchie - LifeSci Advisors,...
Yahoo
Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Rel
Yahoo
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Information: Date: Thursday, March 27, 2
Yahoo
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually) Topline efficacy and safety Phase 2 data expected to be reported at the American Urological Association meeting (AUA), being held April 26-29, 2025 in Las Vegas NDV-01 has the potential to be a first-line therapy for NMIBC, presenting attractiv